The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE: To investigate the efficacy and tolerability of empagliflozin as add-on to metformin and sulfonylurea in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: Patients inadequately controlled on metformin and sulfonylurea (HbA1c ≥7 to ≤10%) were randomized and treated with once-daily empagliflozin 10 mg (n = 225), empagliflozin 25 mg (n = 216), or placebo (n = 225) for 24 weeks. The primary end point was change from baseline in HbA1c at week 24. Key secondary end points were changes from baseline in weight and mean daily glucose (MDG) at week 24. RESULTS: At week 24, adjusted mean (SE) changes from baseline in HbA1c were −0.17% (0.05) for placebo vs. −0.82% (0.05) and −0.77% (0.05) for empagliflozin 10 and 25 mg, respectively (both P < 0.001). Empagliflozin significantly reduced MDG, weight, and systolic (but not diastolic) blood pressure versus placebo. Adverse events were reported in 62.7, 67.9, and 64.1% of patients on placebo and empagliflozin 10 and 25 mg, respectively. Events consistent with urinary tract infection were reported in 8.0, 10.3, and 8.3% of patients on placebo and empagliflozin 10 and 25 mg, respectively (females: 13.3, 18.0, and 17.5%, respectively; males: 2.7, 2.7, and 0%, respectively). Events consistent with genital infection were reported in 0.9, 2.7, and 2.3% of patients on placebo and empagliflozin 10 and 25 mg, respectively (females: 0.9, 4.5, and 3.9%, respectively; males: 0.9% in each group). CONCLUSIONS: Empagliflozin 10 and 25 mg for 24 weeks as add-on to metformin plus sulfonylurea improved glycemic control, weight, and systolic blood pressure and were well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Defining the Relationship Between Plasma Glucose and HbA1c
Rohlfing, C. L., Wiedmeyer, H.-M., Little, R. R., England, J. D., Tennill, A., & Goldstein, D. E. (2002) · Diabetes Care · doi:10.2337/diacare.25.2.275 · Cited by 987
Niskanen, L. K., Laaksonen, D. E., Nyyssönen, K., Alfthan, G., Lakka, H.-M., Lakka, T. A., & Salonen, J. T. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.14.1546 · Cited by 666
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
[Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
Scheen, A. J., & Mathieu, C. (2012) · PubMed · Cited by 581
Phung, O. J. (2010) · JAMA · doi:10.1001/jama.2010.405 · Cited by 520
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513 · cited 2×
“Although efficacious, insulin is associated with side effects such weight gain and hypoglycemia (1,14).”
BackgroundThe role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
DeFronzo, R. A., Davidson, J. A., & Del Prato, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01511.x · Cited by 493
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2008) · Diabetes Care · doi:10.2337/dc08-1171 · Cited by 426
Glucose handling by the kidney
Mather, A., & Pollock, C. (2011) · Kidney International · doi:10.1038/ki.2010.509 · Cited by 375
Heise, T., Seewaldt‐Becker, E., Macha, S., Hantel, S., Pinnetti, S., Seman, L., & Woerle, H. J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12073 · Cited by 273
Self-citationSchiff, M. A., & Holt, V. L. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi078 · Cited by 260
Sosnowski, C., & Janeczko-Sosnowska, E. (2007) · PubMed · Cited by 235
Renal glucose reabsorption inhibitors to treat diabetes
Bailey, C. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.011 · Cited by 217
Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin
Ferrannini, E., Berk, A., Hantel, S., Pinnetti, S., Hach, T., Woerle, H. J., & Broedl, U. C. (2013) · Diabetes Care · doi:10.2337/dc13-0663 · Cited by 214
Self-citationCobin, R. H., Futterweit, W., Ginzburg, S. B., Goodman, N. F., Kleerekoper, M., Licata, A. A., Meikle, A. W., Petak, S. M., Porte, K. L., Sellin, R. V., et al. (2006) · Endocrine Practice · doi:10.4158/ep.12.3.315 · Cited by 185
Boyko, E. J., Fihn, S. D., Scholes, D., Abraham, L., & Monsey, B. (2005) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a000181 · Cited by 182
Ferrannini, E., Seman, L., Seewaldt‐Becker, E., Hantel, S., Pinnetti, S., & Woerle, H. J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12081 · Cited by 181
Self-citationHirji, I., Guo, Z., Andersson, S. W., Hammar, N., & Gomez-Caminero, A. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.06.008 · Cited by 172
Hauber, A. B., Mohamed, A. F., Johnson, F. R., & Falvey, H. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02696.x · Cited by 160
Weight Change in Diabetes and Glycemic and Blood Pressure Control
Feldstein, A. C., Nichols, G. A., Smith, D. H., Stevens, V. J., Bachman, K. H., Rosales, A. G., & Perrin, N. (2008) · Diabetes Care · doi:10.2337/dc08-0426 · Cited by 142
SEMAN, L. J., Macha, S., Nehmiz, G., Simons, G., Ren, B., Pinnetti, S., Woerle, H. J., & Dugi, K. A. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.16 · Cited by 139
Self-citationPollack, M. F., Waterman, F., Bolge, S. C., & Williams, S. A. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.11.023 · Cited by 123
Cederholm, J., Guðbjörnsdóttir, S., Eliasson, B., Zethelius, B., Eeg‐Olofsson, K., & Nilsson, P. M. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283577bdf · Cited by 67
Fate of the beta-cell in the pathophysiology of type 2 diabetes
Campbell, R. K. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09076 · Cited by 64
Morgan, C. L., Jenkins‐Jones, S., Evans, M., Barnett, A. H., Poole, C., & Currie, C. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01552.x · Cited by 49
Shantha, G. P. S., Kumar, A. A., Kahan, S. I., & Cheskin, L. J. (2012) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721712443293 · Cited by 48
The Parathyroid Glands: What The Endocrine Surgeon Should Know
Perrier, N. D. (2011) · Endocrine Practice · doi:10.4158/ep11007.co · Cited by 45
Sulphonyurea as a cause of severe hypoglycaemia in the community
Ng, J. M., Mellor, D. D., Masson, E. A., & Allan, B. J. (2010) · Primary care diabetes · doi:10.1016/j.pcd.2009.12.001 · Cited by 13
Cited by
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationChait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Self-citationBarnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Self-citation
Metadata
- Authors
- Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA-REG METSU Trial Investigators
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-10-15
- Volume
- 36
- Issue
- 11
- Pages
- 3396-3404
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2171471305
- Cited by
- 371
- References
- 34
- FWCI
- 38.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.